Mindbreeze is named “a Leader” in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment
5.12.2024 19:14:00 CET | Business Wire | Press release
Mindbreeze, a global leader in AI-powered enterprise intelligence, is named a Leader in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment (doc #US51541224, December 2024).
Mindbreeze InSpire is transforming the future of enterprise intelligence, revolutionizing how organizations unlock the power of their information. Powered by advanced AI agents, it seamlessly integrates and analyzes structured and unstructured data from diverse systems, turning complexity into clarity. By creating dynamic insight journeys, Mindbreeze InSpire delivers hyper-relevant, context-aware insights tailored to employees’ unique roles and needs—enabling smarter decisions at every level. Beyond streamlining business process transformation, it empowers organizations to fully realize the value of their information ecosystems, driving innovation and securing a competitive edge in today’s fast-paced, data-driven world.
Therefore, “Consider Mindbreeze if you are a large enterprise customer looking for a knowledge management solution that can cater to business areas such as customer service, finance, legal, and HR. Pre-built search applications tailored to specific departments can enhance knowledge creation and search capabilities, while supporting broader business process transformations.”
“We are honored to be recognized as a 'Leader' in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment,” says Daniel Fallmann, founder and CEO of Mindbreeze. “Our focus on delivering tailored insight journeys and flexible deployment options empowers businesses to unlock the true potential of generative AI use cases, seamlessly integrating them into daily workflows across the enterprise. This capability is key to driving business process transformation and automation, putting our customers in a winning position to thrive in a competitive landscape. We are proud of the pivotal role of our solutions in achieving these outcomes.”
Over 2,700 of the world's largest companies across a variety of industries rely on Mindbreeze to manage their information more efficiently and intelligently.
About the IDC MarketScape
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
About Mindbreeze
Mindbreeze is a global leader in AI-powered enterprise intelligence, with locations in Europe and the US and a robust partner network worldwide. Mindbreeze InSpire redefines how organizations access and utilize information. Powered by advanced AI, it transforms complex data into actionable insights, seamlessly connecting and analyzing information across systems.
Unlike traditional solutions, our AI agents deliver hyper-relevant, context-aware insights tailored to unique business needs, enabling smarter, faster decision-making. With unmatched integration capabilities, enterprise-grade data security, and automation at its core, Mindbreeze InSpire maximizes the value of your information ecosystem while driving business innovation.
Trusted by industry leaders and recognized for our cutting-edge technology, Mindbreeze leads the way in unlocking new dimensions of enterprise intelligence.
Learn more at www.mindbreeze.com or follow us on LinkedIn and X @Mindbreeze.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205572409/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom